Estetrol for treatment of female sexual arousal disorders

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
By administering a combination of approximately 14 mg to approximately 25 mg of estradiol components daily, the treatment gap for female sexual arousal disorder (FSAD) has been filled, significantly improving sexual arousal function and satisfaction with sexual activity, and reducing patient suffering.

CN122138833APending Publication Date: 2026-06-02ESTETRA SRL

0 Cites 0 Cited by

Patent Information

Application Number: CN202480060627.8
Authority / Receiving Office: CN · China
Patent Type: Applications(China)
Current Assignee / Owner
Priority Date: 2023-09-21
Filing Date: 2024-09-20
Publication Date: 2026-06-02

Application Information

Patent Timeline

21 Sep 2023

Priority

20 Sep 2024

Application

CN202480060627.8

02 Jun 2026

Publication

CN122138833A

IPC: A61K31/565; A61K31/585; A61K45/06; A61P15/00

CPC: A61K31/565; A61K31/585; A61K45/06; A61P15/00; A61K2300/00

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Organic active ingredients Sexual disorder

Technology Topics

Female Sexual Arousal DisorderSexual arousal disorder

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Currently, there are no effective drugs for treating female sexual arousal disorder (FSAD). Existing research and treatment methods have failed to fully consider diagnostic criteria and patient suffering, resulting in poor treatment outcomes.

Method used

A composition comprising about 14 mg to about 25 mg of estradiol is administered once daily for the treatment of female sexual arousal disorder (FSAD), preferably in oral, sublingual or sublipal dose units, and is suitable for postmenopausal and postmenopausal women.

Benefits of technology

Within 12 weeks, it significantly improved sexual arousal, reduced the severity of sexual dysfunction, increased sexual activity satisfaction, reduced patient distress, and significantly improved sexual function scores.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention relates to therapies for female sexual arousal disorder (FSAD), related compositions, dosage units, and packaging units. In particular, the present invention relates to the use of a composition comprising from about 14 mg to about 25 mg of an estetrol component for the treatment of FSAD. The composition achieves an advantageous effect on patients diagnosed as having FSAD based on a self-reporting questionnaire.

Need to check novelty before this filing date? Find Prior Art